ADAPT study results published in The Lancet Diabetes & Endocrinology show improved glycemic control and treatment satisfaction among those using MiniMed 780G system, compared to insulin injections
The ADAPT study is the first multi-national randomized controlled study evaluating the performance of MiniMed 780G system1 versus standard of care (multiple daily injections (MDI) + continuous glucose monitoring (CGM)) in individuals with type 1 diabetes not currently meeting glycemic targets
The study evaluated 82 individuals who were using MDI and an intermittently scanned continuous glucose monitor (isCGM) to manage their diabetes prior to trial initiation.
On average, individuals enrolled were scanning their isCGM frequently (~9 scans/day) yet had suboptimal HbA1C above 8% at baseline.
At study initiation, half of the participants were randomized to stay on standard of care, and the rest transitioned directly to the MiniMed 780G system. Study results showed improvement in glycemic targets for those that transitioned to the MiniMed 780G system with a significant and sustained 1.4% HbA1C reduction at six months. Those using the Medtronic system also saw a 27.6% absolute increase in Time in Range (6.6 more hours/day in target range) compared to those on standard of care without increased in time in hypoglycemia. This improvement was even greater overnight when the algorithm was in full control.
When comparing A1C results at 6 months, 27.8% of individuals using the MiniMed 780G system in the study achieved an HbA1c below 7%, while no individuals that remained on MDI +isCGM achieved that desired result.
In terms of customer experience, participants using the MiniMed 780G system spent 95.8% of the time in SmartGuard (advanced hybrid closed-loop) and experienced few system exits (only 0.9 SmartGuard exits/week. Additionally, the sensor was being used 92.2% of the time (vs. 87.3% in the standard of care group). The ADAPT study also showed that those that transitioned to the MiniMed 780G system experienced a significant increase in treatment satisfaction and reduction in fear of hypoglycemia.
Overall, results showed that the use of the MiniMed 780G system, even when paired with the Guardian sensor 3 which requires two fingerstick calibrations per day, had significant improvement across all glycemic metrics compared to standard of care and supports the use at early stages in the treatment pathway given the potential benefits of complication avoidance, treatment satisfaction improvements, and reduced fear of hypoglycemia.
The MiniMed 780G system is now available in over 60 countries around the world and is currently being reviewed by the FDA for approval in the U.S.
See- "Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study". Prof Pratik Choudhary, MBBS, Ralf Kolassa, MD,Winfried Keuthage, MD. et al. Show all authors. Published:September 01, 2022DOI:https://doi.org/10.1016/S2213-8587(22)00212-1.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins